Theriva Biologics shareholders approve equity plan increase and elect directors at annual meeting

Theriva Biologics, Inc.

Shareholders approved Amendment No. 3 to increase shares under 2020 Stock Incentive Plan from 2.5M to 4.5M.
All four director nominees elected: Jeffrey J. Kraws, Steven A. Shallcross, John Monahan, Jeffrey Wolf.
Ratified BDO USA, P.C. as independent auditor for FY2025 with 3.61M votes for.
Advisory vote on executive compensation approved; future frequency set at three years.
Vote totals for each proposal are disclosed; broker non-votes totaled 2,212,112 shares.

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.